TTY Biopharm Company Limited (TPEX:4105)

TTY Biopharm Company Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,848	2,773	2,621	2,357	2,222	2,224
Short-Term Investments	54.84	309.02	195.54	326.86	372.65	342.4
Cash & Short-Term Investments	2,902	3,082	2,817	2,684	2,595	2,566
Cash Growth	-7.50%	9.41%	4.93%	3.44%	1.12%	-11.66%
Accounts Receivable	1,272	1,354	1,344	1,227	1,138	1,033
Other Receivables	55.99	23.18	28.81	29.68	13.62	16.48
Receivables	1,328	1,377	1,373	1,257	1,151	1,050
Inventory	1,209	1,270	1,096	1,039	955.01	1,111
Prepaid Expenses	70.68	57.91	79.02	49.89	46.96	64.15
Other Current Assets	354.66	6.67	6.36	5.37	1.15	8.01
Total Current Assets	5,865	5,793	5,370	5,035	4,749	4,799
Property, Plant & Equipment	2,214	2,246	2,287	2,433	2,519	2,585
Long-Term Investments	1,954	1,945	1,578	1,496	1,432	1,458
Goodwill	-	247.9	-	-	-	-
Other Intangible Assets	433.98	123.44	164.01	250.75	124.9	132.9
Long-Term Deferred Tax Assets	58.53	58.52	48.71	47.1	63.72	61.8
Other Long-Term Assets	446.85	448.25	426.94	337.89	407.19	324.72
Total Assets	10,973	10,863	9,875	9,601	9,296	9,361
Accounts Payable	163.76	326.16	294.66	289.4	187.27	159.44
Short-Term Debt	1,000	1,200	1,450	1,370	1,711	1,715
Current Portion of Long-Term Debt	-	400	-	418.85	407.91	16.54
Current Portion of Leases	2.29	0.93	5.86	3.92	7.62	-
Current Income Taxes Payable	336.32	228.8	156.97	149.52	150.39	110.13
Current Unearned Revenue	35.52	34.34	14.23	33.13	39.77	16.29
Other Current Liabilities	2,058	672.18	662.02	652.62	547.55	531.2
Total Current Liabilities	3,596	2,862	2,584	2,917	3,052	2,549
Long-Term Debt	100	100	400	9.6	4.15	412.05
Long-Term Leases	9.47	10.2	3.05	3.04	14.16	-
Long-Term Deferred Tax Liabilities	359.24	359.24	318.75	305.44	260.52	271.83
Other Long-Term Liabilities	19.87	2.44	35.83	91.03	146.23	4.7
Total Liabilities	4,085	3,352	3,369	3,367	3,529	3,283
Common Stock	2,487	2,487	2,487	2,487	2,487	2,487
Additional Paid-In Capital	317.18	317.04	316.62	312.18	311.88	338
Retained Earnings	3,235	3,888	3,182	2,925	2,568	2,759
Comprehensive Income & Other	79.56	58.69	-43.79	-64.78	-198.07	-133.71
Total Common Equity	6,118	6,750	5,941	5,658	5,168	5,450
Minority Interest	769.83	760.49	564.8	574.86	599.38	628.3
Shareholders' Equity	6,888	7,511	6,506	6,233	5,767	6,078
Total Liabilities & Equity	10,973	10,863	9,875	9,601	9,296	9,361
Total Debt	1,112	1,711	1,859	1,805	2,145	2,144
Net Cash (Debt)	1,791	1,371	957.65	878.78	450	422.47
Net Cash Growth	20.97%	43.11%	8.97%	95.28%	6.52%	-56.51%
Net Cash Per Share	7.18	5.50	3.84	3.53	1.81	1.70
Filing Date Shares Outstanding	249.11	248.65	248.65	248.65	248.65	248.65
Total Common Shares Outstanding	249.11	248.65	248.65	248.65	248.65	248.65
Working Capital	2,269	2,931	2,787	2,118	1,698	2,250
Book Value Per Share	24.56	27.15	23.89	22.76	20.78	21.92
Tangible Book Value	5,684	6,379	5,777	5,408	5,043	5,317
Tangible Book Value Per Share	22.82	25.65	23.23	21.75	20.28	21.38
Land	-	902.9	902.9	902.9	902.9	902.9
Buildings	-	1,479	1,461	1,432	1,420	1,311
Machinery	-	1,446	1,432	1,418	1,359	1,234
Construction In Progress	-	0.59	8.95	77.09	95	323.33

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.